Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Abstract Background Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in vir...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2017-11-01
Serie:	BMC Infectious Diseases
Soggetti:	Rilpivirine Raltegravir Elvitegravir/cobicistat Dolutegravir Non-nucleoside reverse transcriptase inhibitors Integrase inhibitors
Accesso online:	http://link.springer.com/article/10.1186/s12879-017-2831-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!